Compare PZZA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | COLL |
|---|---|---|
| Founded | 1984 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1995 | 2015 |
| Metric | PZZA | COLL |
|---|---|---|
| Price | $20.72 | $21.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $45.00 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 1.2M | 799.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $2,068,421,000.00 | $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $44.70 | ★ N/A |
| Revenue Growth | 14.07 | ★ 23.62 |
| 52 Week Low | $20.53 | $22.64 |
| 52 Week High | $55.74 | $50.79 |
| Indicator | PZZA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 22.66 |
| Support Level | N/A | N/A |
| Resistance Level | $24.25 | $35.64 |
| Average True Range (ATR) | 0.77 | 0.97 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 35.44 | 5.39 |
Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.